Form 4: Novo Holdings Boosts MapLight Stake Post-IPO

Novo Holdings A/S converted preferred shares and purchased additional common stock in MapLight Therapeutics' initial public offering, increasing its beneficial ownership.

Summary

• Novo Holdings A/S, a Director and 10% Owner of MapLight Therapeutics, Inc., reported changes in its beneficial ownership.
• On October 28, 2025, Novo Holdings A/S converted 26,191,207 shares of Series C Preferred Stock and 19,734,671 shares of Series D Preferred Stock into a total of 2,733,681 shares of Voting Common Stock.
• The conversion occurred automatically upon the closing of MapLight Therapeutics' initial public offering (IPO) for no additional consideration, on a 1-for-16.8 basis.
• Additionally, on October 28, 2025, Novo Holdings A/S purchased 952,941 shares of Voting Common Stock from the underwriters in the Issuer's IPO at a price of $17 per share.
• Following these transactions, Novo Holdings A/S beneficially owns a total of 3,686,622 shares of Voting Common Stock.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as a major institutional investor and director significantly increased its stake in the company immediately following its IPO, demonstrating strong confidence in MapLight Therapeutics' future.

Positives

• A significant institutional investor, Novo Holdings A/S, increased its stake in MapLight Therapeutics, Inc. following the company's initial public offering, signaling strong confidence.
• The conversion of preferred stock into common stock simplifies the capital structure for Novo Holdings A/S, aligning its interests more directly with common shareholders.
• The purchase of additional common stock at the IPO price of $17 per share demonstrates a commitment to the company's future prospects by a key insider.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the reported transactions.

Industry Context

This transaction occurs in the context of MapLight Therapeutics' initial public offering, indicating the company's transition to a publicly traded entity. The increased stake by Novo Holdings A/S, a prominent life science investor, suggests a positive outlook on MapLight's potential within the biotechnology or pharmaceutical industry.

Related Party Transactions

• Novo Holdings A/S is identified as a Director and a 10% Owner of MapLight Therapeutics, Inc., making the reported transactions related-party dealings.

Stakeholder Impact

• Shareholders: The increased stake by a significant institutional investor like Novo Holdings A/S could be viewed positively, potentially boosting investor confidence and signaling long-term commitment.
• Company: The successful IPO and continued investment from a major shareholder provide capital and validation for MapLight Therapeutics' strategic direction and operations.

Key Dates

Recommendation

The significant increase in beneficial ownership by Novo Holdings A/S, a major institutional investor and director, immediately following MapLight Therapeutics' IPO, signals strong insider confidence. This substantial investment at the IPO price of $17 per share suggests a belief in the company's long-term value and prospects, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

MapLight Therapeutics, Novo Holdings, IPO, Common Stock, Preferred Stock Conversion, Beneficial Ownership, SEC Form 4, Insider Transaction